Finance

Beta
Lists
MNPR:NASDAQ
Monopar Therapeutics Inc
$95.22
-1.96%
(-1.90) 1D
$95.22
0.00% (0.00)
After hours
Closed: Jul 7, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MNPR...
Open
$97.11
High
$98.96
Low
$93.86
Mkt. cap
637.88M
Avg. vol.
148.28K
Volume
163.56K
52-wk high
$105.00
52-wk low
$29.18
EPS
-$1.90
Beta
1.46
Shares outstanding
6.70M
No. of employees
22
Open
$97.11
High
$98.96
Low
$93.86
Mkt. cap
637.88M
Avg. vol.
148.28K
Volume
163.56K
52-wk high
$105.00
52-wk low
$29.18
EPS
-$1.90
Beta
1.46
Shares outstanding
6.70M
No. of employees
22
News stories
From sources across the web
About Monopar Therapeutics Inc
CEO-
Employees22
Founded2014
HeadquartersWilmette, Illinois, United States
SectorBiotechnology
Websitemonopartx.com
Analyst ratings
Based on 9 analysts giving stock ratings to MNPR in the past 3 months
Strong buy
Buy
9
Hold
0
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for MNPR in the last 3 months.
Highest
Current $95.22
$130.00 (+36.53%)
Average
$113.33 (+19.02%)
Lowest
$101.00 (+6.07%)
Analyst
Recommendation
Action
Price target
Projected
Date
Chad Messer
Lake Street
Buy
Maintained
$103.00
+8.2%
06/30/2026
Jeet Mukherjee
BTIG
Buy
Reiterated
$117.00
+22.9%
07/01/2026
Boris Peaker
JonesTrading
Buy
Maintained
$130.00
+36.5%
06/29/2026
Biren Amin
Piper Sandler
Buy
Maintained
$101.00
+6.1%
06/29/2026
Andres Y. Maldonado
H.C. Wainwright
Buy
Reiterated
$105.00
+10.3%
06/29/2026
Etzer Darout
Barclays
Buy
Maintained
$125.00
+31.3%
06/29/2026
Maxwell Skor
Morgan Stanley
Buy
Maintained
$115.00
+20.8%
05/18/2026
Unknown Analyst
Leerink Partners
Buy
Reiterated
$115.00
+20.8%
05/15/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Maintained
$109.00
+14.5%
05/14/2026
Soumit Roy
JonesTrading
Buy
Maintained
$130.00
+36.5%
04/06/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
1.73M
2.59M
3.94M
3.49M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.50M
1.50M
2.21M
1.74M
Operating expense
3.23M
4.09M
6.16M
5.23M
Total operating expenses
3.23M
4.09M
6.16M
5.23M
Operating income
-3.23M
-4.09M
-6.16M
-5.23M
Other non operating income
-
1.00
-1.00
-
EBT including unusual items
-2.45M
-3.44M
-5.20M
-3.89M
EBT excluding unusual items
-2.45M
-3.44M
-5.20M
-3.89M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-2.45M
-3.44M
-5.20M
-3.89M
Net profit margin
-
-
-
-
Earnings per share
-0.35
-0.48
-0.61
-0.46
Interest and investment income
780.77K
655.47K
954.43K
1.33M
Interest expense
-
-
-
-
Net interest expenses
780.77K
655.47K
954.43K
1.33M
Depreciation and amortization charges
-
-
-
-
EBITDA
-
-
-
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer